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of unnecessary catheters could prevent most
episodes of CR-BSI. Total parenteral nutrition
was given to 40% of the patients in the present
study through multi-lumen catheters. This prac-
tice is not recommended by the UK Department of
Health [17], but the most recent USA guidelines
for the prevention of IVC infection did not
consider that specific situation [10].
In conclusion, this study shows clear room for
improvement in decisions concerning the choice,
indications, duration and care of IVCs, and offers
baseline data for the current situation in Europe.
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ABSTRACT
This report describes a meningococcal outbreak in
France caused by Neisseria meningitidis B:15:P1.12
of sequence type 1403, which affected eight young
patients, between November 2000 and February
2002. Epidemiological typing confirmed that a
single strain was responsible. Favourable out-
come, sequelae or death resulted in similar
proportions as in other cases of meningococcal
disease in France during the same period, but
purpura was observed in all eight cases. The
patients were aged between 14 and 28 years,
whereas the median age of patients affected by
other meningococcal strains during this period in
the same area was 60.4 years.
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Neisseria meningitidis is an exclusively human
pathogen, responsible for bacteraemia and men-
ingitis [1]. However, 10–30% of young adults
carry this organism asymptomatically in the
nasopharynx [2], where it can either exist tran-
siently or invade the bloodstream, thus causing
meningococcal disease [3]. Epidemic and spor-
adic cases of meningococcal disease occur world-
wide. Epidemics are caused by the spread of
particular clones (e.g., serogroup A in Asia and
Africa in recent years), while sporadic cases are
caused by genetically heterogeneous strains,
such as those belonging to serogroups B, C, Y
and W135, which account for most infections in
Europe and North America [4]. In France, the
incidence of meningococcal disease has increased
since 1995 (364 invasive cases in 1995 vs. 678 in
2002) [5–7]. Serogroup B, which was responsible
for more than two-thirds of invasive cases in
1997, remains the serogroup isolated most fre-
quently, accounting for c. 54% of cases in 2001,
while 38% of cases were caused by serogroup C
[6].
The Indre-et-Loire department of France has a
mixed urban and rural population, with c. 550 000
inhabitants. All patients suffering from severe
infectious diseases, or less severe but rare infec-
tions, are hospitalised at the Tours University
Hospital. On average, between four and six cases
of meningococcal disease are reported each year
in Indre-et-Loire. However, between November
2000 and February 2002, 13 cases of meningococ-
cal disease, either meningitis or meningococcae-
mia, were recorded (Fig. 1). Eight of the 13 cases
were caused by N. meningitidis B:15:P1.12
(Table 1). The isolates, which were typed by
restriction fragment length polymorphism analy-
sis of the pilA, pilD, crgA, regF and iga genes, all
had the same restriction patterns [8] and belonged
to the same sequence type (ST-1403) according to
multilocus sequence typing [9]. Pulsed-field gel
electrophoresis following macrorestriction with
SpeI endonuclease confirmed their clonal nature.
N. meningitidis B:15:P1.12 strains have been isola-
ted previously in France, but this is the first time
that they have been isolated in Indre-et-Loire or
neighbouring regions.
The first case of N. meningitidis B:15:P1.12
was diagnosed in November 2000, with five
more cases diagnosed in a 3-week period during
January and February 2001, and two further cases
in January and February 2002. All eight patients
had cutaneous lesions, with purpura fulminans or
petechial purpura. Seven of these patients had
classical early signs of an influenza-like syndrome
with fever, followed by vomiting, headache, neck
stiffness and photophobia. Other neurological
signs were noted for five patients (Table 1). The
outcome of the illness following treatment with
b-lactams and gentamicin was favourable for all
patients except patient no. 5. Minor neurological
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Fig. 1. Occurrence of 13 cases of meningococcal disease
caused by Neisseria meningitidis (eight involving the
N. meningitidis B:15:P1.12 strain) in Indre-et-Loire between
November 2000 and February 2002 (NG, non-groupable).
846 Clinical Microbiology and Infection, Volume 10 Number 9, September 2004
 2004 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 10, 843–860
sequelae were also noted for two patients (no
major sequelae were noted). Case no. 5 was
different from the others, as neither an influ-
enza-like syndrome, fever, neck stiffness nor
photophobia was observed. The patient died
before being hospitalised. An autopsy was per-
formed as the haemorrhagic skin lesions were
atypical, and this revealed major pleural, pericar-
dial and peritoneal haemorrhages. Cerebrospinal
fluid and blood cultures were positive for
N. meningitidis in all cases, except case no. 5,
where the strain was isolated following culture of
a meningeal biopsy. The patients were aged
between 14 and 28 years; six were male and
two were female. Epidemiological investigations
revealed that all eight patients lived in the same
area, and that case no. 5 was the friend of the
brother of case no. 6.
The outcomes of these eight cases were similar
in proportion to those of cases of meningococcal
disease recorded in other parts of France, where
the outcome is favourable in 81% of cases (75%
in the present study), major sequelae occur in
5% of cases (0% in the present study, where
there was an absence of major neurological
sequelae), and death occurs in 15% of cases
(12.5% in the present study) [6,7]. Nevertheless,
several major observations can be made. First, all
of the patients involved in the present outbreak
had purpura (petechial, fulminans or extensive),
whereas purpura occurs in only 23% of sero-
group B cases according to the French epidemi-
ological data [6,7]. Second, this unusual strain
spread very rapidly among the population,
causing five cases within a 3-week period fol-
lowing the first case. None of the patients had
any underlying immune deficiency that might
have predisposed them to invasive meningococ-
cal disease, and none had received immunosup-
pressive therapy. No other cases were reported
in 2001 after the short outbreak, and only two
cases were reported in 2002 after an interval of
about a year. In addition, the outbreak was
limited to a small geographical area and did not
spread to neighbouring regions. This was surpri-
sing because the features described above suggest
that the N. meningitidis B:15:P1.12 strain is
epidemic in character. As new clones appear
constantly, this is consistent with the macroevo-
lution of hyper-virulent lineages that emerge at
intervals within the population, and then slowly
diversify as their initially uniform genomes
become increasingly diverse because of highly
localised recombination events [10]. No other
cases have been described since the eighth case,
highlighting the unpredictable changes in men-
ingococcal epidemiology [11,12]. Third, the med-
ian age of the patients infected was 21.7 years
(the youngest patient in the cohort died); no
cases concerned children, neonates or indivi-
duals aged > 28 years. In contrast, the median
age of the five patients infected with other
N. meningitidis strains during the same period
in the same area was 60.4 years (none of these
patients died).
Although there has been an increase in the
use of preventive antibiotic treatment for people
who have come into contact with a patient, data
Table 1. Epidemiological and clinical data for 13 cases of invasive meningococcal disease that occurred in Indre-
et-Loire between November 2000 and February 2002
Date Case no.
Age
(years) Sex Serotype Purpura Neurological signs Other signs Outcome ⁄ sequelae
04 ⁄ 11 ⁄ 00 – 73 F B:NT:P1.5 Not known – – Favourable
08 ⁄ 11 ⁄ 00 1 20 M B:15:P1.12 Ecchymotic Hyperesthaesia Epistaxis Favourable
06 ⁄ 01 ⁄ 01 2 24 M B:15:P1.12 Petechial – – Favourable
20 ⁄ 01 ⁄ 01 3 28 M B:15:P1.12 Yes Occular paralysis – Diplopia
28 ⁄ 01 ⁄ 01 4 22 M B:15:P1.12 Petechial Convulsions Disorientation Diplopia ⁄vertigo
29 ⁄ 01 ⁄ 01 – 60 F NG No No Pneumonia Favourable
01 ⁄ 02 ⁄ 01 5 14 F B:15:P1.12 Petechial – Acute respiratory
disease syndrome
Death
03 ⁄ 02 ⁄ 01 6 19 M B:15:P1.12 Extensive Facial paralysis Necrosis of the toes Favourable
03 ⁄ 02 ⁄ 01 – 81 F C:NT:P1.2,5 Not known – – Favourable
30 ⁄ 04 ⁄ 01 – 52 F C:2a:NST Not known – Shock Favourable
24 ⁄ 01 ⁄ 02 7 22 F B:15:P1.12 Petechial – – Favourable
30 ⁄ 01 ⁄ 02 – 36 F Y:15:P1.12 No – – Favourable
22 ⁄ 02 ⁄ 02 8 25 M B:15:P1.12 Yes Amaurosis ⁄disorientation Shock ⁄ cerebral abscess Favourable
The eight cases caused by the N. meningitidis B:15:P1.12 are numbered in chronological order of their appearance. NG, non-groupable; NT, non-typeable; NST, non-
subtypeable.
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for France in 2001 indicated that while 88% of
family members received antibiotic prophylaxis,
only 58% of colleagues, friends or other people
in close contact with primary cases were given
antibiotics [6]. The outbreak reported in the
present study highlights the importance of very
early prophylaxis to prevent secondary cases
among a family or close contacts. In the present
study, at least one patient (who died) was in
close contact with the brother of another
patient.
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ABSTRACT
Investigation of two cases of invasive meningo-
coccal disease within a single family revealed the
presence of isolates of Neisseria meningitidis phe-
notype C:2b:P1.2,P1.5 belonging to sequence type
(ST) 66. The ST66 clone is a single-locus variant of
the widely distributed ST8 complex, which has
been observed previously in Spain, Belgium,
Australia and New Zealand. This hypervariable
meningococcal lineage has been responsible for
local epidemics worldwide. This is the first report
of ST66 meningococcal isolates of this phenotype
from Poland.
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Neisseria meningitidis is responsible for various
kinds of infections, of which septicaemia and
meningitis are the most severe, but the organism
can also be carried in the nasopharynx of healthy
individuals. Meningococcal infections usually
occur sporadically, but local or large-scale out-
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